Summary
The purpose of this study is to:
- Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
- Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting
- Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Official Title
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Keywords
Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis, RNAi therapeutic, Transthyretin, TTR, Amyloidosis, Hereditary Transthyretin-mediated (hATTR) Amyloidosis, hATTR amyloidosis, Hereditary ATTR amyloidosis, Wild-type amyloidosis, wtATTR amyloidosis, ATTRv amyloidosis, ATTRwt amyloidosis, Polyneuropathy, Familial amyloid polyneuropathies, ATTR, Transthyretin amyloidosis, TTR-mediated amyloidosis, Polyneuropathies, Amyloid neuropathies, Amyloid neuropathies, familial, Amyloidosis, familial, Pre-symptomatic Carriers
